期刊文献+

急诊冠状动脉介入治疗后无复流现象与胰岛素抵抗

Relationship Between Insulin Resistance and No-reflow in Patients with Acute Myocardial Infarction
下载PDF
导出
摘要 目的探讨急性心肌梗死(AMI)急诊经皮冠状动脉介入治疗(PCI)后心肌无复流现象与胰岛素抵抗之间的关系。方法行急诊PCI的ST段抬高型AMI患者109例,其中单光子发射型计算机断层(singlephotonemissioncomputedtomography,SPECT)心肌灌注显像检测出现心肌无复流现象的22例。测定空腹血糖、空腹胰岛素水平、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、肌酐、尿酸水平。评价胰岛素敏感性采用稳态模式评估法(HOMA)及改良的胰岛素敏感性指数(ISI)公式计算。结果AMI无复流组与复流组比较,存在高胰岛素血症(P<0.05)和胰岛素敏感性的降低(P<0.05)。结论AMI急诊PCI术后出现心肌无复流现象的患者存在高胰岛素血症和胰岛素抵抗,胰岛素抵抗在心肌无复流现象的发病中可能发挥一定作用。 Objective To explore the relationship of insulin resistance and no-reflow after treatment with emergency percutaneous coronary intervention(PCI) in ST-elevant acute myocardial infarction. Methods Observing parameters fasting blood glucose(FBG), insulin(INS), total cholesterol(TC), triglycerides(TG), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), creatinine(Cr), uricacid(UA), blood pressure and body mass index(BMI) in 109 cases of acute myocardial infarction. The status of insulin resistance was assessed by homeostasis model assessment(HOMA) and the improved insulin sensitivity index(ISI). Results Fasting insulin levels were significantly higher and insulin sensitivity was lower in no-reflow groups than in reflow groups(P 〈 0.05). Conclusion Patients with no-reflow have an increase in fasting insulin, a decrease in insulin sensitivity. Insulin resistance may play a role in it.
出处 《中国微循环》 北大核心 2006年第5期360-362,共3页 Journal of Chinese Microcirculation
基金 山东省烟台市科学技术计划资助(编号:2005126)
关键词 心肌梗死 血管成形术 无复流 胰岛素抵抗 Myocardial infarction Angioplasty no-reflow insulin resistance
  • 相关文献

参考文献13

  • 1王海涛,杨军,贺岩松,毛庆民,方毅民,王新民,李燕玲,葛淑晶.川芎嗪对兔急性心肌梗死血运重建后心肌“无复流”现象的影响[J].中国微循环,2005,9(2):82-84. 被引量:8
  • 2Saely CH,Aczel S,Marte T,et al.The metabolic syndrome,insulin resistance,and cardiovascular risk in diabetic and nondiabetic patients[J].J Clin Endocrinol Metab.2005,90:5698~5703
  • 3方毅民,任法新,杨军,于滨,刘少荣,刘文波,张传焕.心肌呈色分级评价急性心肌梗死急诊经皮冠状动脉介入治疗的近期疗效[J].中国介入心脏病学杂志,2005,13(3):163-166. 被引量:3
  • 4李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2125
  • 5Taniyama Y,Ito H,Morishita R,et al.Potential of microvascular reperfusion with adjunctive pharmacological intervention:it's impact on myocardial perfusion and functional outcomes in patient's with acute myocardial infarction[J].Drugs.2001,61:437~441
  • 6Resnic FS,Wainstein M,Lee MK,et al.No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention[J].Am Heart J.2003,145:9~11
  • 7Watanabe T,Nanto S,Uematsu M,et al.Prediction of no-reflow phenomenon after successful percutaneous coronary intervention in patients with acute myocardial infarction:intravascular ultrasound findings[J].Circ J.2003,67:667~671
  • 8朱淑贤,钱菊英.冠状动脉微循环灌注障碍和冠脉无复流机理研究[J].微循环技术杂志(临床与实验),2004,8(5):267-269. 被引量:17
  • 9Kendall DM,Harmel AP.The metabolic syndrome,type 2 diabetes,and cardiovascular disease:understanding the role of insulin resistance[J].Am J Manag Care.2002,8(20 Suppl):S6352~6353
  • 10Stout RW.Insulin as a mitogentic factor:role in the pathogenesis of cardiovascular disease[J].Am J Med.1991,90 (Suppl 2A):S62~70

二级参考文献22

  • 1邢启崇.根据丙酮酸激酶变化计算心肌梗塞量的临床及实验研究[J].中华心血管病杂志,1995,23(6):417-420. 被引量:9
  • 2Nakae I, Takaoka A, Mitsunami K, et al. Cardioprotective effects of nicorandil in rabbits anaesthetized with halothane: Potentiation of ischaemic preconditioning via KAT Pchannels [J]. Clin-Exp- Pharmacol-Physiol. 2000,27(10):810~817.
  • 3Golino P, Ragni M, Cirillo P, et al. Recombinant human, active site-blocked factor Ⅶa reduces infarct size and no-eflow phenomenon in rabbits[J].Am J Physiol.2000,278:1508~1510.
  • 4Santoro GM, Valenti R, Buonamici P, et al. Relation between ST-segment changes and myocardial perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial infarction treated with direct angioplasty [ J ]. Am J Carliol. 1998,82:932~937.
  • 5Sheu JR, Kan YC, Hung WC, et al. The antiplatelet activity of tetramethylpyrazine is mediated through activation of NO synthase[J].Life Sci. 2000,67:937~939.
  • 6Feng J, Wu G, Tang S. The effects of tetramethylpyrasine on the incidence of arrnythmias and the release of PGI2and TXA2 in the ischemic rat heart[J]. Planta Med. 1999,65:268~272.
  • 7Imagawa J, Baxter GF, Yellon DM.Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo[J]. Cardiovasc Pharmacol. 1998,31:74~79.
  • 8Pieper GM,Gross GJ. Anti-frec radical and neutrophil-modulating properties of the nitrovasodilater, nicorandil [J]. Cardiovasc Drugs Ther. 1992, 6:225~228.
  • 9Akai K, Wang Y, Satok, et al. Vasodilatory effect of nicorandil coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive pet assium channels [J]. Cardiovasc pharmacal. 1995, 26:541~545.
  • 10Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused integrity and myocardial viability in patients with reperfnsed anterior wall myocardial infarction [ J ]. Am Coll Cardiol.1999,33:654~660.

共引文献2148

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部